<DOC>
	<DOCNO>NCT02471222</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , placebo-controlled , 2-arm , parallel group study ADS-5102 extend release ( ER ) capsule , investigational formulation amantadine , dose daily bedtime treatment walk impairment MS. ADS-5102 design administer daily bed time , ADS-5102 achieve high plasma amantadine concentration early morning , sustain throughout afternoon , low concentration even patient sleep . ADS-5102 design deliver primary treatment effect day , potentially reduce adverse event immediate-release amantadine patient asleep .</brief_summary>
	<brief_title>Safety Efficacy ADS-5102 Patients With Multiple Sclerosis Walking Impairment</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<criteria>Signed current IRBapproved inform consent form ; Male female subject 18 70 year age , inclusive ; Confirmed diagnosis Multiple Sclerosis accord 2010 Revised McDonald criterion ; On stable regimen medication take specifically treat MS least 30 day prior screen , willing continue dose regimens duration study participation ; Stable physical activity level least 30 day prior screen willing continue without change duration study participation ; Maximum EDSS score screen 6.5 ; Sufficient ambulatory ability complete two trial Timed 25 Foot Walk ( T25FW ) screen visit ; A score complete screen T25FW test 8 45 second , inclusive ; Any current allow prescription/nonprescription medication and/or nutritional supplement take regularly must stable dose regimen least 30 day prior screen , subject must willing continue dos regimens study participation ; If take antidepressant , must stable dose least 60 day prior screen . History seizure within 2 year prior screen ; Clinically significant MS relapse onset le 30 day prior screen ; Presence vertigo vestibular dysfunction might compromise ability safely perform T25FW ; Received physical therapy within 30 day prior screen ; Received systemic steroid within 30 day prior screen ; Received dalfampridine , methylphenidate , modafinil , armodafinil , amantadine , and/or product contain amphetamine , treatment specifically fatigue improve walk within 30 day prior screen ; Received botulinum toxin contain product use antispasmodic agent within 3 month prior screen ; History clinically significant hallucination due MS medication other/unknown cause , within 2 year prior screen ; History Bipolar Disorder Psychosis , regardless treatment ; Presence cognitive impairment sufficient , opinion investigator , affect subject 's ability complete study assessment , would subject 's best interest participate study ; History stroke TIA within 2 year prior screen ; History cancer within 5 year ; Presence untreated angle closure glaucoma ; If female , pregnant lactating ; If sexually active female , surgically sterile least 2 year postmenopausal , agree utilize highly effective hormonal method contraception ( IUD , vasectomize male partner also acceptable ) , combination barrier method , screen least 4 week completion study treatment ; Treatment investigational drug device within 30 day prior screen ; Treatment investigational biologic within 6 month prior screen ; Current participation another clinical trial ; Planned elective surgery study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>